GALECTIN THERAPEUTICS INC — Director's Dealing 2012

Apr 27, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2012-04-24

Reporting Person: MAULDIN JOHN F (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-04-24	Common Stock	P	3847	$2.94	Acquired	3847	Indirect
2012-04-25	Common Stock	P	1100	$3.08	Acquired	4947	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.94 to $2.97 inclusive. The reporting person undertakes to provide Galectin Therapeutics Inc., any security holder of Galectin Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.97 to $3.08 inclusive. The reporting person undertakes to provide Galectin Therapeutics Inc., any security holder of Galectin Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F3: On the transaction date stated in column 2 of this row in Table I, the reporting person contributed the shares stated in column 4 of such row to a retirement fund trust of which the reporting person is a trustee and a beneficiary. The reporting person continues to report ownership of all Galectin Therapeutics common stock held by the trust but disclaims beneficial ownership except to the extent of his pecuniary interest therein.